Synthetic biology is a multidisciplinary field that combines principles from biology, engineering, and computer science to design and construct new biological parts, devices, and systems.
OriCiro Genomics announced that it has raised ¥800 million in Series B financing led by The University of Tokyo Edge Capital Partners (UTEC) with participation of ITOCHU Technology Ventures (ITV).
Bacteria could be programmed to efficiently produce drugs, thanks to breakthrough research into synthetic biology using engineering principles, from the University of Warwick and the University of Surrey.